science

List of investigational post-traumatic stress disorder drugs

List of investigational post-traumatic stress disorder drugs is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand List of investigational post-traumatic stress disorder drugs rather than just read about it. In short: This is a list of investigational post-traumatic stress disorder drugs, or drugs that are currently under development for clinical use for the treatment of post-traumatic stress disorder (PTSD) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.

Key takeaways

List of investigational post-traumatic stress disorder drugs belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect List of investigational post-traumatic stress disorder drugs to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of List of investigational post-traumatic stress disorder drugs from memory before moving on to harder problems.

Reference excerpt

This is a list of investigational post-traumatic stress disorder drugs, or drugs that are currently under development for clinical use for the treatment of post-traumatic stress disorder (PTSD) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action [Reference]". This list was last comprehensively updated in September 2025. It is likely to become outdated with time.

Under development

Preregistration Midomafetamine (MDMA; Ecstasy) – serotonin–norepinephrine–dopamine releasing agent, weak serotonin 5-HT2 receptor agonist, and entactogen [1]

Phase 3 Aripiprazole (Abilify; OPC-14597) – atypical antipsychotic (non-selective monoamine receptor modulator) [2] Cyclobenzaprine (KRL-102; TNX-102; Tonmya) – tricyclic antidepressant (monoamine reuptake inhibitor and monoamine receptor modulator) [3]

Phase 2 7-Oxoprasterone (7-keto-DHEA; HBL-9001; HL-9001; At-Ease) – undefined mechanism of action (immunomodulator) [4] [5] Amdiglurax (ALTO-100; NSI-189) – unknown mechanism of action (hippocampal neurogenesis stimulant and indirect brain-derived neurotrophic factor (BDNF) modulator) [6] [7] BI-1358894 – transient receptor potential cation channel TRPC4 and TRPC5 inhibitor [8] Cannabidiol (A-1002-N5S; CBD; Nantheia™) – cannabinoid, various actions [9] CORT-108297 (ADS-108297) – glucocorticoid receptor antagonist [10] Dronabinol (BX-1) – cannabinoid CB1 and CB2 receptor agonist [11] Iloperidone (Fanapt; Fanaptum; Fiapta; HP-873; ILO-522; VYV-683; Zomaril) – atypical antipsychotic (non-selective monoamine receptor modulator) [12] Ketamine intranasal (Ereska; PMI-100; PMI-150; SLS-002; TUR-002) – NMDA receptor antagonist and dissociative hallucinogen [13] Lithium cocrystal (AL-001; LiProSal; lithium salicylate/L-proline cocrystal) – undefined mechanism of action and mood stabilizer (improved formulation of lithium) [14] Methylone (MDMC; TSND-201) – serotonin–norepinephrine–dopamine releasing agent and entactogen Midomafetamine/citalopram (MDMA/citalopram) – serotonin–norepinephrine–dopamine releasing agent, weak serotonin 5-HT2 receptor agonist, and entactogen followed by a selective serotonin reuptake inhibitor Psilocybin (COMP-360; COMP360) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and psychedelic hallucinogen [15] Psilocybin (MYCO-001, MYCO-003) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and psychedelic hallucinogen [16] Soclenicant (BNC-210; IW-2143) – α7-nicotinic acetylcholine receptor antagonist [17] SRX-246 (API-246) – vasopressin V1A receptor antagonist [18] Xenon (NBTX-001) – NMDA receptor antagonist [19]

Phase 1/2 PT-00114 – corticotropin-releasing hormone (CRH) inhibitor [20]

Phase 1 Dexmedetomidine (BXCL-501; Igalmi; KalmPen) – α2-adrenergic receptor agonist [21] ENX-205 – dopamine D2 and D3 receptor antagonist and serotonin 5-HT1A and 5-HT2A receptor agonist [22] (R)-Midomafetamine ((R)-MDMA; EMP-01) – serotonin–norepinephrine releasing agent, weak serotonin 5-HT2 receptor agonist, and entactogen [23] Mirodenafil (AR-1001) – phosphodiesterase PDE5 inhibitor [24]

Preclinical 2-Bromo-LSD (bromolysergide; BOL-148; BETR-001, TD-0148A) – non-hallucinogenic serotonin 5-HT2A receptor agonist and other actions ART-2612 (ART2612) – FABP5 inhibitor [25] BMB-202 – serotonin 5-HT2A receptor agonist [26] Cycloserine/lurasidone (NRX-101) – combination of cycloserine (NMDA receptor partial agonist) and lurasidone (atypical antipsychotic or non-selective monoamine receptor modulator) [27] Cyproheptadine/prazosin (KT-110; Periactine/Alpress) – combination of cyproheptadine (H1 receptor antagonist, muscarinic acetylcholine receptor antagonist, serotonin receptor antagonist, other actions) and prazosin (α1-adrenergic receptor antagonist) [28] GM-3009 (ibogaine analogue(s); GMX-3009) – various actions Leu-enkephalin (leucine enkephalin; Envelta; METDoloron; NES-100; NM-0127; NM-127; PES200) – δ-opioid receptor agonist [29] Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor, antiglucocorticoid) and oxazepam (GABAA receptor positive allosteric modulator, benzodiazepine) Midomafetamine microneedle transdermal patch (MDMA; "ecstasy") – serotonin–norepinephrine–dopamine releasing agent, weak serotonin 5-HT2 receptor agonist, and entactogen NB-127 – undefined mechanism of action [30] NNI-351 – DYRK kinase inhibitor, nerve growth factor (NGF) stimulant [31] Prabotulinumtoxin A (ABP-450; DWP-450; Evosyal; Jeuveau; Nabota; Nuceiva) – acetylcholine release inhibitor and neuromuscular blocking agent [32] Research programme: neurotransmitter modulators - Awakn Life Sciences (AWKN-SDN-14) – serotonin–norepinephrine–dopamine reuptake inhibitors [33] TN-001 – non-hallucinogenic serotonin 5-HT2A receptor partial agonist and serotonin 5-HT2B receptor antagonist and neuroplastogen

Not under development

Development suspended Osanetant (ACER-801; SR-142801; SR-142806) – neurokinin NK3 receptor antagonist [34]

… excerpt ends here. Continue reading the full article.

Worked examples

Example 1 — a first encounter with List of investigational post-traumatic stress disorder drugs

Start with the simplest possible case. Write down what List of investigational post-traumatic stress disorder drugs claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to List of investigational post-traumatic stress disorder drugs before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about List of investigational post-traumatic stress disorder drugs ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of List of investigational post-traumatic stress disorder drugs

In research: List of investigational post-traumatic stress disorder drugs appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses List of investigational post-traumatic stress disorder drugs in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: List of investigational post-traumatic stress disorder drugs is common in secondary-school and first-year university syllabi. It links to neighbouring topics Experimental psychiatric drugs, Lists of investigational drugs, so understanding it makes those chapters shorter.
In everyday life: Look for List of investigational post-traumatic stress disorder drugs outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “List of investigational post-traumatic stress disorder drugs” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study List of investigational post-traumatic stress disorder drugs in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what List of investigational post-traumatic stress disorder drugs means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain List of investigational post-traumatic stress disorder drugs out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is List of investigational post-traumatic stress disorder drugs in simple terms?

Why does List of investigational post-traumatic stress disorder drugs matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study List of investigational post-traumatic stress disorder drugs?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on List of investigational post-traumatic stress disorder drugs.